![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » EMEA GRANTS PTC ORPHAN DRUG DESIGNATION
EMEA GRANTS PTC ORPHAN DRUG DESIGNATION
July 8, 2005
PTC Therapeutics (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced that PTC124 has been granted orphan drug status for the treatment of Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF) by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA).
BioSpace (http://www.biospace.com/news_story.cfm?StoryID=20543020&full=1)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct